A Ferring UK spokesman said he had already held preliminary meetings with four agencies, which he declined to identify, about 2005 PR ambitions for the brand.
‘Two or three’ agencies are likely to go head-to-head for the account in a pitch in around one month’s time for a contract that could span both PR and med ed work.
The brand PR review follows a decision at Ferring’s corporate headquarters in Denmark to hand PR work for the product – which internationally carries the name Minirin – to its local operating companies.
Minirin’s international PR was formerly handled by Burson-Marsteller, whose London office this week confirmed that it has ceased to work on the brand.
The bulk of B-M’s work on Minirin, which is registered in 27 European countries, took place during 2003.
Ferring is using Helen Lawn & Associates in a contract to handle international PR, excluding the US and Japan, for its liver disease product Glypressin. The work was formerly handled in-house.